Swedish Orphan Biovitrum AB (B6E) Stock Statistics & Valuation Metrics

Swedish Orphan Biovitrum AB has a market cap or net worth of €14.43B. The enterprise value is €178.24K.

Swedish Orphan Biovitrum AB has 357,412,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Swedish Orphan Biovitrum AB’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 14.02%.

The current PE Ratio of Swedish Orphan Biovitrum AB is 174.7. Swedish Orphan Biovitrum AB’s PEG ratio is -2.73.

In the last 12 months, Swedish Orphan Biovitrum AB had revenue of 28.24B and earned 478.00M in profits. Earnings per share was 1.39.

In the last 12 months, operating cash flow was 7.86B and capital expenditures -607.00M, giving a free cash flow of 7.25B billion.

Swedish Orphan Biovitrum AB pays an annual dividend of ―, resulting in a dividend yield of ―

Swedish Orphan Biovitrum AB upcoming earnings date is Oct 27, 2026, Before Open (Confirmed).

Swedish Orphan Biovitrum AB as a current ratio of 0.90, with Debt / Equity ratio of 47.21%

In the past 12 months, Swedish Orphan Biovitrum AB has paid -442.00M in taxes.

Swedish Orphan Biovitrum AB EV to EBITDA ratio is 11.41, with an EV/FCF ratio of 14.67.

Swedish Orphan Biovitrum AB has €1.08B in cash and marketable securities with €17.59B in debt, giving a net cash position of -€16.50B billion.

Gross margin is 44.17%, with operating margin of 28.50%, and net profit margin of 1.69%.

The average price target for Swedish Orphan Biovitrum AB is €45.93, which is 11.43% higher than the current price. The consensus rating is Strong Buy